Summary & Overview
HCPCS J0121: Omadacycline Injection, 1 mg
HCPCS Level II code J0121 denotes the parenteral formulation of omadacycline, billed per 1 mg unit. As an on‑label injectable antimicrobial option, this code matters nationally for hospital outpatient departments, infusion centers, and clinic-based administrations where specialty antibiotics are delivered. Accurate reporting of unit-based HCPCS drugs affects payer adjudication, inventory tracking, and national expenditure accounting for newer antimicrobial agents. Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise orientation to the clinical use and billing context for J0121, including expected service settings and the unit-based nature of reimbursement. The publication outlines typical payer coverage considerations, common modifiers used with drug administration claims (listed separately), and the kinds of benchmarks and policy updates that influence payment and utilization oversight. Clinical context addresses the role of omadacycline as an injectable antibiotic option, while billing context highlights unit reporting and site-of-service implications. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code J0121 represents injection, omadacycline, 1 mg. This code is used to report administration of the antibiotic omadacycline in parenteral form. The service type is drug administration / injectable antimicrobial therapy, and the typical site of service is outpatient infusion or clinic-based injection services.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting with a confirmed or suspected bacterial infection for which intravenous or injectable omadacycline is clinically indicated. The patient may arrive to an outpatient infusion center, hospital inpatient ward, emergency department observation unit, or skilled nursing facility for administration. Prior to administration, a clinician documents indication, allergy history, weight, renal and hepatic status, and confirms culture and sensitivity results when available. Pharmacy prepares the J0121 units based on the ordered dose in milligrams, and nursing obtains venous access (peripheral IV or existing central line), verifies patient identity, reviews infusion instructions (rate, dilution), and monitors for infusion-related reactions. Typical workflow steps: medication order entry with exact mg dose converted to J0121 units, pharmacy compounding, bedside nursing verification and administration, post-infusion monitoring for adverse events, and documentation of lot number and expiration for billing compliance. Usual sites of service include outpatient infusion centers, hospital inpatient units, emergency departments, and long-term care facilities. The patient scenario commonly includes diagnoses such as community-acquired bacterial pneumonia, skin and soft tissue infection (including acute bacterial skin and skin structure infection), or other susceptible infections where omadacycline is indicated and IV or injectable therapy is used.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|